KMT9-IN-1
KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma[1].
Product Specifications
CAS Number
2625406-61-1
UNSPSC
12352005
Target
Epigenetic Reader Domain
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O[C@@H]1[C@H](O)[C@@H](CN(CC[C@H](N)C(OCC)=O)CCCNCCC2=CC=C(OC3=CC=C(Cl)C=C3)C(F)=C2)C[C@H]1N4C=CC5=C(NC)N=CN=C54
Molecular Formula
C36H47ClFN7O5
Molecular Weight
712.25
References & Citations
[1]Wang S, et al. Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity. J Med Chem. 2025 Jul 10;68 (13) :13295-13320.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
(S)-N-(tert-Butanesulfinyl) Levamfetamine-d3
CD137 / 4-1BB / TNFRSF9 (4-1BB/3201), CF740 conjugate, 0.1mg/mL
